CN105960247A - 用抗vegf darpin治疗眼病的方法 - Google Patents

用抗vegf darpin治疗眼病的方法 Download PDF

Info

Publication number
CN105960247A
CN105960247A CN201480060463.5A CN201480060463A CN105960247A CN 105960247 A CN105960247 A CN 105960247A CN 201480060463 A CN201480060463 A CN 201480060463A CN 105960247 A CN105960247 A CN 105960247A
Authority
CN
China
Prior art keywords
days
doses
dose
binding protein
interval
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480060463.5A
Other languages
English (en)
Chinese (zh)
Inventor
T·霍曼
J·奇塔姆
S·惠特卡普
E·利帕
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of CN105960247A publication Critical patent/CN105960247A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN201480060463.5A 2013-11-05 2014-11-04 用抗vegf darpin治疗眼病的方法 Pending CN105960247A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361900246P 2013-11-05 2013-11-05
US61/900,246 2013-11-05
US201462016620P 2014-06-24 2014-06-24
US62/016,620 2014-06-24
PCT/US2014/063951 WO2015069668A1 (en) 2013-11-05 2014-11-04 Method of treating conditions of the eye with an anti-vegf darpin

Publications (1)

Publication Number Publication Date
CN105960247A true CN105960247A (zh) 2016-09-21

Family

ID=51947485

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480060463.5A Pending CN105960247A (zh) 2013-11-05 2014-11-04 用抗vegf darpin治疗眼病的方法

Country Status (14)

Country Link
US (4) US20150126458A1 (cg-RX-API-DMAC10.html)
EP (2) EP3628324A1 (cg-RX-API-DMAC10.html)
JP (3) JP2016536369A (cg-RX-API-DMAC10.html)
KR (1) KR20160070164A (cg-RX-API-DMAC10.html)
CN (1) CN105960247A (cg-RX-API-DMAC10.html)
AU (2) AU2014346921A1 (cg-RX-API-DMAC10.html)
CA (1) CA2927012A1 (cg-RX-API-DMAC10.html)
DK (1) DK3065761T3 (cg-RX-API-DMAC10.html)
ES (1) ES2773317T3 (cg-RX-API-DMAC10.html)
HU (1) HUE047910T2 (cg-RX-API-DMAC10.html)
PL (1) PL3065761T3 (cg-RX-API-DMAC10.html)
PT (1) PT3065761T (cg-RX-API-DMAC10.html)
TW (1) TWI729970B (cg-RX-API-DMAC10.html)
WO (1) WO2015069668A1 (cg-RX-API-DMAC10.html)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114075290A (zh) * 2022-01-20 2022-02-22 南京鼓楼医院 Cd40靶向结合蛋白、其编码核酸以及用途
CN114269366A (zh) * 2019-06-04 2022-04-01 分子伴侣公司 重组fap结合蛋白及其用途
CN121910909A (zh) * 2026-03-27 2026-04-24 中国医学科学院病原生物学研究所 工程化多肽注射系统及其在靶向递送抗菌肽中的用途

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2828739T3 (es) 2006-04-07 2021-05-27 Aerpio Pharmaceuticals Inc Anticuerpos que se unen a la proteína tirosina fosfatasa beta humana (HPTP-beta) y sus usos
MX363351B (es) 2011-10-13 2019-03-20 Aerpio Therapeutics Inc Un agente de unión a hptp?-ecd para usarse en el tratamiento de síndrome de fuga vascular.
PT2846836T (pt) 2012-05-07 2019-10-29 Allergan Inc Método de tratamento de dmi em doentes refratários à terapia anti-vegf
RS67656B1 (sr) 2018-05-10 2026-02-27 Regeneron Pharma Formulacije koje sadrže visoke koncentracije fuzionog proteina vegf receptora
EP3856245A4 (en) 2018-09-24 2022-10-26 EyePoint Pharmaceuticals, Inc. MULTISPECIFIC ANTIBODIES AGAINST HPTP - BETA (VE-PTP) AND VEGF
PE20240329A1 (es) 2019-06-05 2024-02-27 Regeneron Pharma Dispositivos y metodos para administracion de dosis de precision
WO2022073072A1 (en) * 2020-10-07 2022-04-14 Implicit Bioscience Limited Methods and agents for the treatment of ocular disease
KR20230083299A (ko) 2020-10-08 2023-06-09 노탈 비전 엘티디. Oct 가이드 치료
US12649031B2 (en) 2021-09-08 2026-06-09 Regeneron Pharmaceuticals, Inc. Methods for delivering agents with pre-filled syringes to minimize intraocular inflammation
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010060748A1 (en) * 2008-11-03 2010-06-03 Molecular Partners Ag Binding proteins inhibiting the vegf-a receptor interaction
WO2011135067A1 (en) * 2010-04-30 2011-11-03 Molecular Partners Ag Modified binding proteins inhibiting the vegf-a receptor interaction

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101433715B (zh) 1999-06-08 2013-04-17 里珍纳龙药品有限公司 具有改善的药物动力学特性的修饰嵌合多肽
EP1332209B1 (en) 2000-09-08 2009-11-11 Universität Zürich Collections of repeat proteins comprising repeat modules
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
CA2644712C (en) 2006-03-06 2016-09-13 Amunix, Inc. Unstructured recombinant polymers and uses thereof
EP2111228B1 (en) 2007-02-02 2011-07-20 Bristol-Myers Squibb Company 10Fn3 domain for use in treating diseases associated with inappropriate angiogenesis
US8563521B2 (en) 2007-06-21 2013-10-22 Technische Universitat Munchen Biological active proteins having increased in vivo and/or in vitro stability
PT2846836T (pt) * 2012-05-07 2019-10-29 Allergan Inc Método de tratamento de dmi em doentes refratários à terapia anti-vegf

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010060748A1 (en) * 2008-11-03 2010-06-03 Molecular Partners Ag Binding proteins inhibiting the vegf-a receptor interaction
WO2011135067A1 (en) * 2010-04-30 2011-11-03 Molecular Partners Ag Modified binding proteins inhibiting the vegf-a receptor interaction

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
范伟杰 等: "血管内皮生长因子在兔眼前段缺血模型中的表达", 《临床眼科杂志》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114269366A (zh) * 2019-06-04 2022-04-01 分子伴侣公司 重组fap结合蛋白及其用途
CN114075290A (zh) * 2022-01-20 2022-02-22 南京鼓楼医院 Cd40靶向结合蛋白、其编码核酸以及用途
CN121910909A (zh) * 2026-03-27 2026-04-24 中国医学科学院病原生物学研究所 工程化多肽注射系统及其在靶向递送抗菌肽中的用途

Also Published As

Publication number Publication date
US20210008158A1 (en) 2021-01-14
US20150126458A1 (en) 2015-05-07
JP2022107628A (ja) 2022-07-22
WO2015069668A1 (en) 2015-05-14
US20170157207A1 (en) 2017-06-08
PL3065761T3 (pl) 2020-05-18
CA2927012A1 (en) 2015-05-14
KR20160070164A (ko) 2016-06-17
JP2016536369A (ja) 2016-11-24
DK3065761T3 (da) 2020-02-17
US20220175881A1 (en) 2022-06-09
TW201609125A (zh) 2016-03-16
PT3065761T (pt) 2020-02-21
ES2773317T3 (es) 2020-07-10
TWI729970B (zh) 2021-06-11
HUE047910T2 (hu) 2020-05-28
AU2020202968A1 (en) 2020-05-21
JP2020169191A (ja) 2020-10-15
EP3065761A1 (en) 2016-09-14
EP3628324A1 (en) 2020-04-01
EP3065761B1 (en) 2020-01-08
AU2014346921A1 (en) 2016-06-02

Similar Documents

Publication Publication Date Title
US20220175881A1 (en) Method of treating conditions of the eye with an anti-vegf darpin
US20220096596A1 (en) Method of treating amd in patients refractory to anti-vegf therapy
US10646542B2 (en) Modified binding proteins inhibiting the VEGF-A receptor interaction
KR101698362B1 (ko) Ｖｅｇｆ－ａ 수용체 상호작용을 억제하는 결합 단백질
HK1179876B (en) Modified binding proteins inhibiting the vegf-a receptor interaction

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20160921